Glycol chitosan-based fluorescent theranostic nanoagents for cancer therapy

Marine Drugs

Volumn 12, Issue 12, 2014, Pages 6038-6057

  Rhee, Jin Kyu ^a   Park, Ok Kyu ^a   Lee, Aeju ^b   Yang, Dae Hyeok ^c   Park, Kyeongsoon ^a  

^a Korea Basic Science Institute (KBSI)   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Cancer; Fluorescence; Glycol chitosan; Nanosystem; Theranostics

Indexed keywords

BILE ACID; CHEMICALS AND DRUGS; CHITOSAN; DIAGNOSTIC AGENT; DRUG CARRIER; FULLERENE DERIVATIVE; GLYCOL CHITOSAN NANOPARTICLE; ISOTOPE; NANOPARTICLE; NUCLEIC ACID; PHOTOSENSITIZING AGENT; SMALL INTERFERING RNA; SMALL MOLECULAR DRUG; UNCLASSIFIED DRUG; FLUORESCENT DYE; GLYCOL-CHITOSAN;

CANCER DIAGNOSIS; CANCER THERAPY; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEM; FLUORESCENCE; FLUORESCENCE IMAGING; HEALTH CARE COST; HUMAN; MOLECULAR STABILITY; MULTIMODALITY CANCER THERAPY; NANOMEDICINE; NONHUMAN; PHOTOSENSITIVITY; PROCESS DESIGN; REPRODUCIBILITY; REVIEW; TREATMENT RESPONSE; ANIMAL; NEOPLASMS; PROCEDURES;

ANIMALS; CHITOSAN; DIAGNOSTIC IMAGING; FLUORESCENT DYES; HUMANS; NANOPARTICLES; NEOPLASMS;

EID: 84919936090     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md12126038     Document Type: Review

References (76)

1. Sumer, B.; Gao, J. Theranostic nanomedicine for cancer. Nanomedicine 2008, 3, 137-140.
2. McCarthy, J.R. The future of theranostic nanoagents. Nanomedicine 2009, 4, 693-695.
3. McCarthy, J.R. Multifunctional agents for concurrent imaging and therapy in cardiovascular disease. Adv. Drug Deliv. Rev. 2010, 62, 1023-1030.
4. Fang, C.; Zhang, M. Nanoparticle-based theragnostics: Integrating diagnostic and therapeutic potentials in nanomedicine. J. Control. Release 2010, 146, 2-5.
5. Ahmed, N.; Fessi, H.; Elaissari, A. Theranostic applications of nanoparticles in cancer. Drug Discov. Today 2012, 17, 928-934.
6. Muthu, M.S.; Leong, D.T.; Mei, L.; Feng, S.S. Nanotheranostics-Application and further development of nanomedicine strategies for advanced theranostics. Theranostics 2014, 4, 660-677.
7. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 2000, 65, 271-284.
8. Allen, T.M.; Cullis, P.R. Drug delivery systems: Entering the mainstream. Science 2004, 303, 1818-1822.
9. Emerich, D.F.; Thanos, C.G. The pinpoint promise of nanoparticle-based drug delivery and molecular diagnosis. Biomol. Eng. 2006, 23, 171-184.
10. Koo, Y.E.; Reddy, G.R.; Bhojani, M.; Schneider, R.; Philbert, M.A.; Rehemtulla, A.; Ross, B.D.; Kopelman, R. Brain cancer diagnosis and therapy with nanoplatforms. Adv. Drug Deliv. Rev. 2006, 58, 1556-1577.
11. Weissleder, R. Molecular imaging in cancer. Science 2006, 312, 1168-1171.
12. Weissleder, R.; Pittet, M.J. Imaging in the era of molecular oncology. Nature 2008, 452, 580-589.
13. Lee, D.E.; Koo, H.; Sun, I.C.; Ryu, J.H.; Kim, K.; Kwon, I.C. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem. Soc. Rev. 2012, 41, 2656-2672.
14. Chen, X.; Conti, P.S.; Moats, R.A. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res. 2004, 64, 8009-8014.
15. Weissleder, R. A clearer vision for in vivo imaging. Nat. Biotechnol. 2001, 19, 316-317.
16. Shukla, S.K.; Mishra, A.K.; Arotiba, O.A.; Mamba, B.B. Chitosan-based nanomaterials: A state-of-the-art review. Int. J. Biol. Macromol. 2013, 59, 46-58.
17. Son, Y.J.; Jang, J.S.; Cho, Y.W.; Chung, H.; Park, R.W.; Kwon, I.C.; Kim, I.S.; Park, J.Y.; Seo, S.B.; Park, C.R.; et al. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J. Control. Release 2003, 91, 135-145.
18. Hyung Park, J.; Kwon, S.; Lee, M.; Chung, H.; Kim, J.H.; Kim, Y.S.; Park, R.W.; Kim, I.S.; Bong Seo, S.; Kwon, I.C.; et al. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: In vivo biodistribution and anti-tumor activity. Biomaterials 2006, 27, 119-126.
19. Kim, J.H.; Kim, Y.S.; Kim, S.; Park, J.H.; Kim, K.; Choi, K.; Chung, H.; Jeong, S.Y.; Park, R.W.; Kim, I.S.; et al. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel. J. Control. Release 2006, 111, 228-234.
20. Park, J.H.; Kwon, S.; Nam, J.O.; Park, R.W.; Chung, H.; Seo, S.B.; Kim, I.S.; Kwon, I.C.; Jeong, S.Y. Self-assembled nanoparticles based on glycol chitosan bearing 5beta-cholanic acid for RGD peptide delivery. J. Control. Release 2004, 95, 579-588.
21. Kim, J.H.; Kim, Y.S.; Park, K.; Kang, E.; Lee, S.; Nam, H.Y.; Kim, K.; Park, J.H.; Chi, D.Y.; Park, R.W.; et al . Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials 2008, 29, 1920-1930.
22. Yoo, H.S.; Lee, J.E.; Chung, H.; Kwon, I.C.; Jeong, S.Y. Self-assembled nanoparticles containing hydrophobically modified glycol chitosan for gene delivery. J. Control. Release 2005, 103, 235-243.
23. Huh, M.S.; Lee, S.Y.; Park, S.; Lee, S.; Chung, H.; Lee, S.; Choi, Y.; Oh, Y.K.; Park, J.H.; Jeong, S.Y.; et al. Tumor-homing glycol chitosan/polyethylenimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J. Control. Release 2010, 144, 134-143.
24. Park, K.; Kim, J.H.; Nam, Y.S.; Lee, S.; Nam, H.Y.; Kim, K.; Park, J.H.; Kim, I.S.; Choi, K.; Kim, S.Y.; et al . Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J. Control. Release 2007, 122, 305-314.
25. Lee, S.; Ryu, J.H.; Park, K.; Lee, A.; Lee, S.Y.; Youn, I.C.; Ahn, C.H.; Yoon, S.M.; Myung, S.J.; Moon, D.H.; et al. Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo . Nano Lett. 2009, 9, 4412-4416.
26. Nam, T.; Park, S.; Lee, S.Y.; Park, K.; Choi, K.; Song, I.C.; Han, M.H.; Leary, J.J.; Yuk, S.A.; Kwon, I.C.; et al. Tumor targeting chitosan nanoparticles for dual-modality optical/MR cancer imaging. Bioconjugate Chem. 2010, 21, 578-582.
27. Veiseh, O.; Gunn, J.W.; Zhang, M. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv. Drug Deliv. Rev. 2010, 62, 284-304.
28. Lewandrowski, K.U.; Gresser, J.D.; Wise, D.L.; Trantol, D.J. Bioresorbable bone graft substitutes of different osteoconductivities: A histologic evaluation of osteointegration of poly(propylene glycol-co-fumaric acid)-based cement implants in rats. Biomaterials 2000, 21, 757-764.
29. Bamrungsap, S.; Zhao, Z.; Chen, T.; Wang, L.; Li, C.; Fu, T.; Tan, W. Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system. Nanomedicine 2012, 7, 1253-1271.
30. Zhang, Y.; Zhang, M. Calcium phosphate/chitosan composite scaffolds for controlled in vitro antibiotic drug release. J. Biomed. Mater. Res. 2002, 62, 378-386.
31. Na, J.H.; Koo, H.; Lee, S.; Min, K.H.; Park, K.; Yoo, H.; Lee, S.H.; Park, J.H.; Kwon, I.C.; Jeong, S.Y.; Kim, K. Real-time and non-invasive optical imaging of tumor-targeting glycol chitosan nanoparticles in various tumor models. Biomaterials 2011, 32, 5252-5261.
32. Barshtein, G.; Ben-Ami, R.; Yedgar, S. Role of red blood cell flow behavior in hemodynamics and hemostasis. Expert Rev. Cardiovasc. Ther. 2007, 5, 743-752.
33. Kim, K.; Kim, J.H.; Park, H.; Kim, Y.S.; Park, K.; Nam, H.; Lee, S.; Park, J.H.; Park, R.W.; Kim, I.S.; et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J. Control. Release 2010, 146, 219-227.
34. Saravanakumar, G.; Min, K.H.; Min, D.S.; Kim, A.Y.; Lee, C.M.; Cho, Y.W.; Lee, S.C.; Kim, K.; Jeong, S.Y.; Park, K.; et al. Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: Synthesis, characterization, and in vivo biodistribution. J. Control. Release 2009, 140, 210-217.
35. Kim, J.H.; Kim, Y.S.; Park, K.; Lee, S.; Nam, H.Y.; Min, K.H.; Jo, H.G.; Park, J.H.; Choi, K.; Jeong, S.Y.; et al . Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J. Control. Release 2008, 127, 41-49.
36. Min, K.H.; Park, K.; Kim, Y.S.; Bae, S.M.; Lee, S.; Jo, H.G.; Park, R.W.; Kim, I.S.; Jeong, S.Y.; Kim, K.; et al. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Control. Release 2008, 127, 208-218.
37. Hwang, H.Y.; Kim, I.S.; Kwon, I.C.; Kim, Y.H. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J. Control. Release 2008, 128, 23-31.
38. Rasool, A.A.; Hussain, A.A.; Dittert, L.W. Solubility enhancement of some water-insoluble drugs in the presence of nicotinamide and related compounds. J. Pharm. Sci. 1991, 80, 387-393.
39. Lee, B.S.; Park, K.; Park, S.; Kim, G.C.; Kim, H.J.; Lee, S.; Kil, H.; Oh, S.J.; Chi, D.; Kim, K.; et al. Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: Importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug. J. Control. Release 2010, 147, 253-260.
40. Kelkar, S.S.; Reineke, T.M. Theranostics: Combining imaging and therapy. Bioconjugate Chem. 2011, 22, 1879-1903.
41. Niidome, T.; Huang, L. Gene therapy progress and prospects: Nonviral vectors. Gene Ther. 2002, 9, 1647-1652.
42. Lee, S.Y.; Huh, M.S.; Lee, S.; Lee, S.J.; Chung, H.; Park, J.H.; Oh, Y.K.; Choi, K.; Kim, K.; Kwon, I.C. Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing. J. Control. Release 2010, 141, 339-346.
43. Lee, S.J.; Huh, M.S.; Lee, S.Y.; Min, S.; Lee, S.; Koo, H.; Chu, J.U.; Lee, K.E.; Jeon, H.; Choi, Y.; et al. Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment. Angew. Chem. 2012, 51, 7203-7207.
44. Sharma, S.K.; Chiang, L.Y.; Hamblin, M.R. Photodynamic therapy with fullerenes in vivo: Reality or a dream? Nanomedicine 2011, 6, 1813-1825.
45. Agostinis, P.; Berg, K.; Cengel, K.A.; Foster, T.H.; Girotti, A.W.; Gollnick, S.O.; Hahn, S.M.; Hamblin, M.R.; Juzeniene, A.; Kessel, D.; et al. Photodynamic therapy of cancer: An update. Cancer J. Clin. 2011, 61, 250-281.
46. Dolmans, D.E.; Fukumura, D.; Jain, R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer 2003, 3, 380-387.
47. Henderson, B.W.; Dougherty, T.J. How does photodynamic therapy work? Photochem. Photobiol. 1992, 55, 145-157.
48. Josefsen, L.B.; Boyle, R.W. Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics. Theranostics 2012, 2, 916-966.
49. Moore, C.M.; Pendse, D.; Emberton, M. Photodynamic therapy for prostate cancer-A review of current status and future promise. Nat. Clin. Pract. Urol. 2009, 6, 18-30.
50. Awan, M.A.; Tarin, S.A. Review of photodynamic therapy. Surgeon 2006, 4, 231-236.
51. Sun, Y.; Chen, Z.L.; Yang, X.X.; Huang, P.; Zhou, X.P.; Du, X.X. Magnetic chitosan nanoparticles as a drug delivery system for targeting photodynamic therapy. Nanotechnology 2009, 20, 135102.
52. Guillemard, V.; Saragovi, H.U. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res. 2001, 61, 694-699.
53. Bechet, D.; Couleaud, P.; Frochot, C.; Viriot, M.L.; Guillemin, F.; Barberi-Heyob, M. Nanoparticles as vehicles for delivery of photodynamic therapy agents. Trends Biotechnol. 2008, 26, 612-621.
54. Lee, S.J.; Park, K.; Oh, Y.K.; Kwon, S.H.; Her, S.; Kim, I.S.; Choi, K.; Lee, S.J.; Kim, H.; Lee, S.G.; et al. Tumor specificity and therapeutic efficacy of photosensitizer-encapsulated glycol chitosan-based nanoparticles in tumor-bearing mice. Biomaterials 2009, 30, 2929-2939.
55. Lee, S.J.; Koo, H.; Jeong, H.; Huh, M.S.; Choi, Y.; Jeong, S.Y.; Byun, Y.; Choi, K.; Kim, K.; Kwon, I.C. Comparative study of photosensitizer loaded and conjugated glycol chitosan nanoparticles for cancer therapy. J. Control. Release 2011, 152, 21-29.
56. Bae, Y.H.; Yin, H. Stability issues of polymeric micelles. J. Control. Release 2008, 131, 2-4.
57. Lee, S.J.; Koo, H.; Lee, D.E.; Min, S.; Lee, S.; Chen, X.; Choi, Y.; Leary, J.F.; Park, K.; Jeong, S.Y.; et al . Tumor-homing photosensitizer-conjugated glycol chitosan nanoparticles for synchronous photodynamic imaging and therapy based on cellular on/off system. Biomaterials 2011, 32, 4021-4029.
58. Baskin, J.M.; Prescher, J.A.; Laughlin, S.T.; Agard, N.J.; Chang, P.V.; Miller, I.A.; Lo, A.; Codelli, J.A.; Bertozzi, C.R. Copper-free click chemistry for dynamic in vivo imaging. Proc. Natl. Acad. Sci. USA 2007, 104, 16793-16797.
59. Chang, P.V.; Prescher, J.A.; Sletten, E.M.; Baskin, J.M.; Miller, I.A.; Agard, N.J.; Lo, A.; Bertozzi, C.R. Copper-free click chemistry in living animals. Proc. Natl. Acad. Sci. USA 2010, 107, 1821-1826.
60. Prescher, J.A.; Bertozzi, C.R. Chemistry in living systems. Nat. Chem. Biol. 2005, 1, 13-21.
61. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. A stepwise huisgen cycloaddition process: Copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem. 2002, 41, 2596-2599.
62. Tornoe, C.W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 2002, 67, 3057-3064.
63. Agard, N.J.; Prescher, J.A.; Bertozzi, C.R. A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. J. Am. Chem. Soc. 2004, 126, 15046-15047.
64. Ngo, J.T.; Champion, J.A.; Mahdavi, A.; Tanrikulu, I.C.; Beatty, K.E.; Connor, R.E.; Yoo, T.H.; Dieterich, D.C.; Schuman, E.M.; Tirrell, D.A. Cell-selective metabolic labeling of proteins. Nat. Chem. Biol. 2009, 5, 715-717.
65. Cheng, Z.; Al Zaki, A.; Hui, J.Z.; Muzykantov, V.R.; Tsourkas, A. Multifunctional nanoparticles: Cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338, 903-910.
66. Gartner, Z.J.; Bertozzi, C.R. Programmed assembly of 3-dimensional microtissues with defined cellular connectivity. Proc. Natl. Acad. Sci. USA 2009, 106, 4606-4610.
67. Bertozzi, C.R.; Kiessling, L.L. Chemical glycobiology. Science 2001, 291, 2357-2364.
68. Lee, S.; Koo, H.; Na, J.H.; Han, S.J.; Min, H.S.; Lee, S.J.; Kim, S.H.; Yun, S.H.; Jeong, S.Y.; Kwon, I.C.; et al. Chemical tumor-targeting of nanoparticles based on metabolic glycoengineering and click chemistry. ACS Nano 2014, 8, 2048-2063.
69. Park, S.Y.; Baik, H.J.; Oh, Y.T.; Oh, K.T.; Youn, Y.S.; Lee, E.S. A smart polysaccharide/drug conjugate for photodynamic therapy. Angew. Chem. 2011, 50, 1644-1647.
70. Jensen, A.W.; Wilson, S.R.; Schuster, D.I. Biological applications of fullerenes. Bioorg. Med. Chem. 1996, 4, 767-779.
71. Kwag, D.S.; Oh, N.M.; Oh, Y.T.; Oh, K.T.; Youn, Y.S.; Lee, E.S. Photodynamic therapy using glycol chitosan grafted fullerenes. Int. J. Pharm. 2012, 431, 204-209.
72. Kwag, D.S.; Park, K.; Oh, K.T.; Lee, E.S. Hyaluronated fullerenes with photoluminescent and antitumoral activity. Chem. Commun. 2013, 49, 282-284.
73. Kim, S.; Lee, D.J.; Kwag, D.S.; Lee, U.Y.; Youn, Y.S.; Lee, E.S. Acid pH-activated glycol chitosan/fullerene nanogels for efficient tumor therapy. Carbohydr. Polym. 2014, 101, 692-698.
74. Lee, B.R.; Oh, K.T.; Baik, H.J.; Youn, Y.S.; Lee, E.S. A charge-switched nano-sized polymeric carrier for protein delivery. Int. J. Pharm. 2010, 392, 78-82.
75. Kean, T.; Thanou, M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv. Rev. 2010, 62, 3-11.
76. Rodrigues, S.; Dionísio, M.; López, C.R.; Grenha, A. Biocompatibility of chitosan carriers with application in drug delivery. J. Funct. Biomater. 2012, 3, 615-641.